Table 2 Subgroup Analysis in proportion of relapse free patients
Subgroups (no. of studies) | |||
|---|---|---|---|
Study type | Effect size (95% C.I.) | I2 | Subgroup difference |
Observational Study (6) | 68.6% (95% CI: 0.44–0.94), p < 0.001 | 82.69% | 0.19 |
Randomized Controlled Trial (1) | 86.4% (95% CI: 0.78–0.95), p < 0.001 | NA | |
Duration of follow-up | |||
< 20 months (3) | 73.9% (95% CI:0.49–0.98), p < 0.001 | 53.54% | 0.94 |
> 20 months (3) | 70.8% (95% CI:0.33–1.09), p < 0.001 | 89.55% | |
Percentage of AQP-4 positivity | |||
All (100%) (4) | 64.6% (95% CI:0.27–1.02), p = 0.001 | 86.32% | 0.31 |
Not All (100%) (3) | 84.3% (95% CI: 0.76–0.92), p < 0.001 | 0% | |
Site of Injection | |||
Intravenous (5) | 67.1% (95% CI:0.45–0.89), p < 0.001 | 64.68% | p = 0.001 |
Subcutaneous (1) | 100% (95% CI:0.98–1.02), p < 0.001 | NA | |
Mixed (1) | 66.7% (95% CI:0.40–0.93), p < 0.001 | NA | |